Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
Price : $35 *
At a glance
- Drugs Liraglutide (Primary) ; CD26 antigen inhibitors
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 25 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2014 Planned End Date changed from 1 Nov 2013 to 1 Mar 2014 as reported by the ClinicalTrials.gov record.